An intraoperative methylene blue test can guide patient selection for totally tubeless percutaneous nephrolithotomy

This study demonstrates that an intraoperative methylene blue test is a simple, high positive-predictive-value tool for guiding real-time patient selection for totally tubeless percutaneous nephrolithotomy in both mini and standard procedures.

The Gist

Imagine your kidneys are like a busy kitchen where a chef (the surgeon) is trying to clear out a massive pile of rocks (kidney stones) that have clogged the sink.

Traditionally, after the chef finishes cleaning, they leave a giant drain pipe (a nephrostomy tube) sticking out of the patient's back and a straw (a ureteral stent) inside the plumbing to make sure water can flow out while the kitchen heals. While this keeps things safe, it's incredibly uncomfortable for the patient, causes pain, and keeps them in the hospital longer.

Doctors have been trying a new method called "Totally Tubeless" PCNL. This is like cleaning the kitchen and then just closing the door, trusting that the sink will drain on its own. It's much more comfortable for the patient, but surgeons are nervous: What if the drain is actually clogged? What if the water backs up and floods the kitchen?

This paper introduces a clever, low-tech "ink test" to solve that worry.

The "Blue Ink" Test: A Simple Traffic Check

Here is how the test works, using a simple analogy:

Imagine the kidney is a house, and the ureter is the driveway leading to the street (the bladder). The surgeon wants to know: Is the driveway clear, or is there a traffic jam?

1. The Setup: Once the stones are crushed and removed, the surgeon removes all the tools from the kidney.
2. The Injection: They take a syringe filled with 10 mL of bright blue dye (methylene blue) and inject it into the kidney.
3. The Timer: They start a stopwatch.
4. The Result:
   • PASS (Green Light): If the blue dye shows up in the patient's bladder catheter within 2 minutes, it means the "driveway" is wide open. The water is flowing freely. The surgeon can confidently say, "No drain pipe needed!" and send the patient home without tubes.
   • FAIL (Red Light): If the blue dye doesn't show up in 2 minutes, it means there's a blockage (maybe a leftover stone fragment or swelling). The surgeon then plays it safe and leaves the drain pipe in place.

What the Study Found

The researchers tested this "Blue Ink" idea on 91 patients across four different hospitals. They split them into two groups:

• Mini-PCNL: Using a smaller, more precise tool (like a tiny vacuum cleaner).
• Standard PCNL: Using a larger, more traditional tool (like a big industrial vacuum).

The Results were encouraging:

• Mini-PCNL Group: 75% of patients passed the test. Most of these patients went home the same day with no tubes at all. Only two had minor hiccups (like a temporary blockage from a tiny stone fragment), but they were fixed without surgery.
• Standard PCNL Group: Only about 39% passed the test. This makes sense because larger tools cause more swelling, making it harder for the "driveway" to clear immediately. However, for those who did pass, the test worked perfectly to keep them safe without tubes.

Why This Matters

Think of this test as a "safety net" for surgeons.

Before this, deciding whether to leave a patient tubeless was mostly a guess based on the surgeon's gut feeling. "I think it looks okay, so I'll take the risk."

Now, the surgeon has an objective, real-time traffic report.

• If the blue dye flows: They know for a fact the path is clear. They can remove the tubes with confidence.
• If the blue dye stalls: They know to leave the drain pipe in, preventing a dangerous backup.

The Bottom Line

This study shows that a simple, cheap, and fast blue dye test can help surgeons decide who is safe enough to go home without painful tubes after kidney stone surgery.

• For Patients: Less pain, faster recovery, and a shorter hospital stay.
• For Doctors: A clear, scientific way to make a tough decision, reducing the fear of leaving a patient without a safety drain.

It's a small drop of blue ink that could lead to a huge improvement in how we treat kidney stones!

Technical Summary

1. Problem Statement

Percutaneous Nephrolithotomy (PCNL) is the standard of care for large and complex renal calculi. Traditionally, the procedure concludes with the placement of a nephrostomy tube or ureteral stent to ensure drainage, tamponade bleeding, and allow access for second-look procedures. However, these devices are associated with significant morbidity, including increased postoperative pain, prolonged hospitalization, and higher infection risks.

While "totally tubeless" PCNL (omitting both nephrostomy tubes and stents) has been shown to improve recovery and reduce analgesic requirements, its adoption remains limited. The primary barrier is the lack of objective, real-time intraoperative criteria to determine if a patient's urinary system is sufficiently patent and draining to safely forego drainage tubes. Surgeons currently rely on subjective judgment, leading to hesitation in omitting tubes due to fears of postoperative obstruction, urine extravasation, or retained stone fragments.

2. Methodology

This was a multi-institutional study involving 91 adult patients undergoing PCNL at four centers (University of Colorado, UCSF, University of Michigan, and Universitas Indonesia Hospital).

• Study Design: Prospective observational study evaluating an intraoperative decision-support tool.
• Patient Cohort:
  • Mini-PCNL (N=60): 16 Fr access sheath.
  • Standard PCNL (N=31): 24+ Fr access sheath.
  • Exclusion Criteria: Prior reconstructive surgery, chronic pain, or cases requiring ureteral dilation.
• The Methylene Blue (MB) Test Protocol:
  • Performed immediately after stone clearance and removal of all instruments from the ureter.
  • A Foley catheter was placed in the bladder.
  • Injection: 10–15 mL of diluted methylene blue (approx. 1:10 with saline) was injected into the renal pelvis via the percutaneous tract.
  • Success Criteria ("Pass"): Visualization of blue dye in the bladder catheter within 2 minutes.
  • Failure Criteria ("Fail"): No dye visualization within 2 minutes.
• Management Based on Test Results:
  • Mini-PCNL "Pass": Patients were managed totally tubeless (no stent, no nephrostomy), provided the kidney was visually stone-free and there was no active bleeding or injury.
  • Standard PCNL "Pass": Patients underwent simulated totally tubeless management. A nephrostomy tube was placed but capped to allow rapid drainage if obstruction occurred postoperatively.
  • "Fail": Standard drainage (stent or nephrostomy tube) was placed per surgeon preference.
• Outcomes: Primary outcome was postoperative complications within 7 days, specifically focusing on obstruction (UTI, fever, flank pain, AKI, need for re-intervention).

3. Key Contributions

• Objective Decision-Making Tool: Introduces a simple, low-cost, real-time functional test (MB test) to assess antegrade urinary drainage, replacing subjective surgeon judgment.
• Differentiation by Tract Size: Provides data distinguishing the feasibility of tubeless management between mini-PCNL and standard PCNL.
• Safety Validation: Demonstrates that a positive MB test correlates with a high safety profile for omitting drainage tubes, even in complex cases, provided specific criteria are met.
• Multi-Center Validation: Confirms the reproducibility of the test across diverse institutions and surgeon experience levels.

4. Results

• Test Pass Rates:
  • Mini-PCNL: 75% (45/60) passed the MB test.
  • Standard PCNL: 38.7% (12/31) passed the MB test.
  • Statistical Significance: The difference in pass rates was statistically significant ($p = 0.001$), suggesting mini-PCNL is more amenable to tubeless management.
• Outcomes for "Pass" Cases:
  • Mini-PCNL (Totally Tubeless, N=40):
    • 38 patients (95%) were discharged on the same day (LOS 0).
    • Complications (2/40, 5%):
      1. One patient had a distal ureteral stone fragment causing flank pain (resolved spontaneously).
      2. One patient had urinary retention and AKI (resolved with temporary catheterization).
    • No surgical re-intervention was required.
  • Standard PCNL (Simulated Tubeless, N=8):
    • 5 totally tubeless, 3 capped nephrostomy.
    • Complications: One transient creatinine elevation (resolved spontaneously); one required uncapping of the nephrostomy due to steinstrasse (resolved without further intervention).
    • No infectious or obstructive complications requiring surgical re-intervention occurred.
• Overall Safety: No subjects who passed the MB test required surgical re-intervention for obstruction or infection within the 7-day follow-up.

5. Significance and Clinical Implications

• Facilitating Broader Adoption: The MB test addresses the primary psychological and clinical barrier to totally tubeless PCNL by providing an objective "green light" for surgeons to omit drainage tubes.
• Enhanced Recovery: Successful application of the test allows for same-day discharge, reduced analgesic use, and improved patient comfort, aligning with modern Enhanced Recovery After Surgery (ERAS) protocols.
• Resource Utilization: Reducing unnecessary tube placement decreases hospital costs and resource utilization associated with tube-related complications (pain, infection, accidental dislodgement).
• Strategic Application: The study suggests that while the test is highly effective for Mini-PCNL (where 75% passed and were safely managed tubeless), it serves as a critical safety filter for Standard PCNL, where the lower pass rate (38.7%) indicates a higher risk of obstruction, warranting more conservative management (e.g., capped tubes) or standard drainage for "fail" cases.
• Limitations & Future Directions: The study notes that the negative predictive value was not tested (patients who failed were not left tubeless). Future randomized controlled trials are needed to validate the test's negative predictive value and refine protocols for standard PCNL.

Conclusion: The intraoperative methylene blue test is a validated, simple, and effective method to identify candidates for totally tubeless PCNL, particularly in mini-PCNL cases, thereby improving patient outcomes and facilitating the transition to ambulatory stone surgery.